Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
geneva vte score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–2
  • High Risk3–33
Direct Clinical Answer

The Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis calculator is designed for bedside predicting the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may.

Clinical Guidelines & Evidence

Predicts the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may not require anticoagulation

Clinical Indication

The Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis is indicated for bedside clinical practice to support Predicts the need for venous thromboembolism (VTE) prophylaxis in hospitalized medical patients by assessing risk factors to identify patients who would benefit from thromboprophylaxis versus those at low risk who may not require anticoagulation. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Consider contraindications to anticoagulation before starting prophylaxis.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Score = Sum of all risk factors (2 points for major factors: cardiac failure, respiratory failure, recent stroke <3mo, recent MI <4wks, acute infectious disease, acute rheumatic disease, active malignancy, myeloproliferative syndrome, nephrotic syndrome, prior VTE, hypercoagulable state; 1 point for minor factors: immobilization ≥3d, recent travel >6h, age >60y, obesity BMI>30, chronic venous insufficiency, pregnancy, hormonal therapy, dehydration)

Input Parameters

NameTypeRequiredDescription
cardiac_failurestringYesPresence of cardiac failure
respiratory_failurestringYesPresence of respiratory failure
recent_strokestringYesRecent stroke within 3 months
recent_myocardial_infarctionstringYesRecent myocardial infarction within 4 weeks
acute_infectious_diseasestringYesAcute infectious disease including sepsis
acute_rheumatic_diseasestringYesAcute rheumatic disease
active_malignancystringYesActive malignancy
myeloproliferative_syndromestringYesMyeloproliferative syndrome
nephrotic_syndromestringYesNephrotic syndrome
prior_vte_historystringYesPrior history of venous thromboembolism
known_hypercoagulable_statestringYesKnown hypercoagulable state
immobilizationstringYesImmobilization for 3 or more days with less than 30 minutes of walking per day
recent_travelstringYesRecent travel longer than 6 hours
age_over_60stringYesAge greater than 60 years
obesitystringYesObesity with BMI greater than 30 kg/m²
chronic_venous_insufficiencystringYesChronic venous insufficiency
pregnancystringYesPregnancy
hormonal_therapystringYesHormonal therapy (estrogen-containing contraceptives or hormone replacement therapy)
dehydrationstringYesDehydration

Score Interpretation & Guidance

RangeStageDescription
0–2Low RiskLow risk for VTE
3–33High RiskHigh risk for VTE

Evidence-Based References (EBM)

  • Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost. 2006;4(4):915-916. doi: 10.1111/j.1538-7836.2006.01818.x.DOI: 10.1111/j.1538-7836.2006.01818.x
  • Nendaz M, Spirk D, Kucher N, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost. 2014;111(3):531-538. doi: 10.1160/TH13-05-0427.DOI: 10.1160/TH13-05-0427
  • Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79. doi: 10.1378/chest.09-3081.DOI: 10.1378/chest.09-3081

Related calculators